Concepedia

Pierre Raboisson

PR

Statistics

Publications

68

Citations

3.8K

H-Index

37

Active since

1996

Affiliations

Janssen (Belgium)(Current)

Johnson & Johnson (United States)

Medivir (Sweden)

Centre National de la Recherche Scientifique

KU Leuven

Pierre Raboisson is an author at Janssen (Belgium) specializing in pharmacology, medicinal chemistry, and drug discovery.

Publications per year

1996–2024

68

Publications

68

Discovery and Development of Simeprevir (TMC435), a HCV NS3/4A Protease Inhibitor

Åsa Rosenquist, Bertil Samuelsson, Per-Ola Johansson et al. · Journal of Medicinal Chemistry · 2014 · 215 citations

, , +17

<i>In Vitro</i> Resistance Profile of the Hepatitis C Virus NS3/4A Protease Inhibitor TMC435

Oliver Lenz, Thierry Verbinnen, Tse‐I Lin et al. · Antimicrobial Agents and Chemotherapy · 2010 · 211 citations · Full text

, , +17

A pan-serotype dengue virus inhibitor targeting the NS3–NS4B interaction

Suzanne J. F. Kaptein, Olivia Goethals, Dominik Kiemel et al. · Nature · 2021 · 192 citations · Full text

, , +13

In Vitro Activity and Preclinical Profile of TMC435350, a Potent Hepatitis C Virus Protease Inhibitor

Tse‐I Lin, Oliver Lenz, Gregory Fanning et al. · Antimicrobial Agents and Chemotherapy · 2009 · 190 citations · Full text

, , +17

The Substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro Are Selected by a Protease Inhibitor <i>In Vitro</i> and Confer Resistance To Nirmatrelvir

Dirk Jochmans, Kim Donckers, Antitsa Stoycheva et al. · mBio · 2023 · 170 citations · Full text

, , +16

1–5 of 68